Levels of CD14dimCD16+ non‐classical monocytes, HLA‐DR++ nonclassical monocytes, and HLA‐DR++ intermediate monocytes at the time of first radiographic evaluation correlated with better PFS in a trial of αPD‐1 therapy as a first‐line treatment in patients with advanced NSCLC (n = 65) with <50% tumour expression of PD‐L1.71 This evidence concerns the gene CD274 and neoplasm.